肝素的临床应用规则

来源 :第6届中国医师协会全国检验与临床学术会议暨国际检验与临床高峰论坛 | 被引量 : 0次 | 上传用户:cutuf
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
其他文献
CD4+ Th17 cells can activate CD8+ cytotoxic T lymphocytes (CTL) and induce antitumor immunity leading to eradication of established tumors.However, the mechanism of CTL activation by Th 17 cells and t
会议
Oral squamous cell carcinoma (OSCC) and other head and neck squamous carcinoma constitute a microenvironment characterized by the infiltration of distinct inflammatory cells, predominantly T cells, in
会议
Pancreaticobiliary maljunction (PBM) or choledochal cyst is a high risk factor for biliary tract cancer especially in Asian people.In PBM, since the pancreatic duct and bile duct converge outside the
会议
A major problem with cisplatin treatment is the development of acquired-drug resistance of the tumour cells.Verotoxin1 (VT-1) exerts its cytotoxicity by targeting the membrane glycolipid globotriasosy
会议
Breast cancers with erbB2 alterations are more aggressive and typically more resistant to traditional therapeutic agents.Thus, the erbB2 receptor is an excellent target for breast cancer therapy.Herce
会议
Hepatitis B virus (HBV) X antigen (HBx) plays an important role in the development of human hepatocellular carcinoma (HCC).We used an HBx transgenic mouse model to conduct genome-wide gene expression
会议
Next-Generation Sequencing is being widely applied in many research areas such as genome assembly, gene mutaion discovery, epigenetics, SNP discovery, transcriptome (RNA-Seq) and gene expression analy
会议
Nanowires have been used to inject in a controlled way singlet oxygen into specific parts of a single cell.The new technique is based on growth of zinc oxide nanowires on a pipettee covered with a pho
会议
Current proteomic technologies are limited with respect to absolute quantification of protein levels and the amount of material required: large ensembles of cells are used.By working with population a
会议
TRAIL receptor agonists have been demonstrated as effective tumor therapeutics.Monoclonal antibodies against TRAIL receptor 1 or 2, such as Mapatumumab, Lexatumumab from Human Genome Sciences, Conatum
会议